Welcome to our dedicated page for LivaNova PLC Ordinary Shares news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on LivaNova PLC Ordinary Shares stock.
LivaNova PLC (symbol: LIVN) is a global leader in medical technology, with nearly five decades of experience and an unwavering mission to enhance patient outcomes around the world. Headquartered in London, UK, LivaNova operates in more than 100 countries and employs approximately 3,000 professionals. The company is publicly traded on the NASDAQ stock exchange.
Specializing in advanced circulatory support, cardiopulmonary solutions, and neuromodulation therapies, LivaNova offers a diverse portfolio of products designed to tackle serious health conditions. Their offerings include surgical heart valves, heart-lung machines, oxygenation equipment, and devices for treating conditions like treatment-resistant epilepsy and depression.
LivaNova was formed through a merger between Cyberonics from the US and Sorin from Italy, combining their strengths to create a powerhouse in medical devices. The company has since streamlined its focus by divesting its cardiac rhythm management and heart valve businesses, allowing it to concentrate on its core strengths.
The company’s commitment to innovation is evident through its continuous development of breakthrough treatments and advanced technologies. By emphasizing both clinical and economic value, LivaNova aims to benefit patients, healthcare professionals, and healthcare systems alike. Approximately half of LivaNova’s revenues are generated from the US, with Europe contributing 21%, and the rest coming from other global markets.
LivaNova’s expertise and global presence make it a significant player in the medical technology sector, dedicated to creating products and therapies that transform lives every day.
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1, 2021. This event showcases LivaNova's commitment to innovation in medical technology. The pre-recorded discussion will be available on LivaNova's website, remaining accessible for 90 days. With nearly 3,000 employees and a presence in over 100 countries, LivaNova aims to deliver life-changing medical technologies for patients worldwide. For more details, visit www.livanova.com.
LivaNova PLC (NASDAQ:LIVN) announced a ruling from the Court of Appeal of Milan, requiring the company to pay €453 million (around $519 million) for environmental liabilities linked to a former parent company, SNIA. LivaNova disputes the decision and plans to appeal to the Italian Supreme Court. This civil action may impact LivaNova's financial standing but the outcome of the appeal regarding joint liability is pending. The company maintains a strong global presence, operating in over 100 countries.
LivaNova PLC (NASDAQ:LIVN), a leading medical technology company, announces its CEO, Damien McDonald, will present at two significant healthcare conferences: the Stifel 2021 Virtual Healthcare Conference on November 17 at 10 a.m. Eastern and the Jefferies 2021 London Healthcare Conference on November 18 at 3 a.m. Eastern. Both presentations will be accessible via webcasts on LivaNova’s website, with replays available for 90 days. LivaNova, headquartered in London, employs around 3,000 people and operates in over 100 countries.
LivaNova PLC (NASDAQ:LIVN) announced a virtual Investor Day on December 7 from 8 a.m. to 12 p.m. CT. Executive leadership will present the long-range business plan aimed at maximizing growth and shareholder value. Additionally, the event will include overviews of the company’s franchises and strategic pipeline initiatives, with opportunities for Q&A sessions. Interested attendees can register via the LivaNova website. Following the event, a replay and presentation materials will be available online for one year.
LivaNova PLC (NASDAQ: LIVN) reported a 5.5% increase in third-quarter 2021 sales, reaching $253.2 million. Excluding the divested Heart Valves business, sales grew by 15.7%. Adjusted diluted EPS was $0.68, up from $0.38 in Q3 2020. The company raised 2021 guidance, projecting 8-11% net sales growth and adjusted EPS of $2.00 to $2.10. Operating income rose significantly to $17.9 million, with adjusted operating income at $47.9 million, a 49.1% increase. LivaNova also improved its cash flow and financial flexibility through an equity offering, retiring a $450 million term loan.
LivaNova PLC (NASDAQ:LIVN) will host a conference call on
LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will speak at the Baird 2021 Global Healthcare Conference on September 15, 2021, at 9:40 a.m. ET. The presentation will be available via live webcast on the LivaNova website. Participants are encouraged to log in 10 minutes early. A replay will be available for 30 days post-event. LivaNova, headquartered in London, is dedicated to improving patient outcomes with innovative medical technologies, employing around 3,000 staff globally.
LivaNova PLC (NASDAQ:LIVN) has announced the early retirement of its $450 million senior secured term loan, repaying the principal along with a $35.6 million make-whole premium. This repayment reduces interest expenses by approximately $39 million annually. Funding came from a recent equity offering and cash reserves. Additionally, LivaNova executed a $125 million revolving credit facility with Goldman Sachs for general corporate purposes. For 2021, the company anticipates adjusted diluted earnings per share between $1.75 to $2.05 and adjusted free cash flow between $50 to $70 million.
LivaNova PLC (NASDAQ:LIVN) has priced an underwritten offering of 3,636,364 ordinary shares at $82.50 each, with a potential additional 545,454 shares. The net proceeds are projected to be about $280.1 million, aiming to partially repay a $450 million senior secured term loan. This offering is set to close on August 6, 2021, and is backed by an effective shelf registration statement. Goldman Sachs, Barclays, and UBS are the joint bookrunners, with shares available solely to qualified investors.
LivaNova PLC (NASDAQ:LIVN) has announced an underwritten offering of $300 million of ordinary shares, with an option for underwriters to purchase an additional 15%. Proceeds will be used to help repay a $450 million senior secured term loan, which incurred $9.7 million in interest expenses in Q2 2021. The offering is conducted under an effective shelf registration statement with the SEC. Joint bookrunners include Goldman Sachs, Barclays, and UBS.
FAQ
What is the current stock price of LivaNova PLC Ordinary Shares (LIVN)?
What is the market cap of LivaNova PLC Ordinary Shares (LIVN)?
What does LivaNova PLC specialize in?
Where is LivaNova PLC headquartered?
On which stock exchange is LivaNova PLC listed?
How many countries does LivaNova operate in?
How many employees does LivaNova PLC have?
What types of products does LivaNova offer?
What significant mergers have shaped LivaNova?
What percentage of LivaNova's revenue comes from the US market?
What recent changes has LivaNova made to its business focus?
How does LivaNova benefit the healthcare industry?
